1-anilino-8-naphthalenesulfonate has been researched along with Osteoporosis in 5 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Urso, C | 1 |
| Brucculeri, S | 1 |
| Caimi, G | 1 |
| Rossi, F | 1 |
| Bellini, G | 1 |
| Luongo, L | 1 |
| Torella, M | 1 |
| Mancusi, S | 1 |
| De Petrocellis, L | 1 |
| Petrosino, S | 1 |
| Siniscalco, D | 1 |
| Orlando, P | 1 |
| Scafuro, M | 1 |
| Colacurci, N | 1 |
| Perrotta, S | 1 |
| Nobili, B | 1 |
| Di Marzo, V | 1 |
| Maione, S | 1 |
| Guelcher, SA | 1 |
| Patel, V | 1 |
| Gallagher, KM | 1 |
| Connolly, S | 1 |
| Didier, JE | 1 |
| Doctor, JS | 1 |
| Hollinger, JO | 1 |
| Taggart, HM | 1 |
| Applebaum-Bowden, D | 1 |
| Haffner, S | 1 |
| Warnick, GR | 1 |
| Cheung, MC | 1 |
| Albers, JJ | 1 |
| Chestnut, CH | 1 |
| Hazzard, WR | 1 |
| Lark, RK | 1 |
| Lester, GE | 1 |
| Ontjes, DA | 1 |
| Blackwood, AD | 1 |
| Hollis, BW | 1 |
| Hensler, MM | 1 |
| Aris, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Evaluating Single, High-dose Pharmacokinetics/Pharmacodynamics of Vitamin D3 in CF[NCT03734744] | 6 participants (Actual) | Interventional | 2019-06-17 | Terminated (stopped due to Clinical research currently on hold) | |||
| Double-blind Randomized Study to Determine the Efficacy of Intramuscular Vitamin D3 Supplementation in Tropical Calcific Pancreatitis[NCT00956839] | Phase 4 | 40 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients in each group with serum 25 hydroxy vitamin D >30 ng/ml (NCT00956839)
Timeframe: 6 months post intervention
| Intervention | percentage of patients (Number) |
|---|---|
| IM Vitamin D3 3,00,000 Units | 85 |
| IM Vitamin D3 6,00,000 Units | 29 |
| Oral Vitamin D3 | 0 |
Serum total calcium (mg/dL) at time points 0, 1, 3 and 6 months (NCT00956839)
Timeframe: 0, 1, 3, 6 months post intervention
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| baseline | 1 month | 3 months | 6 months | |
| IM Vitamin D3 3,00,000 Units | 9.20 | 9.28 | 9.40 | 9.40 |
| IM Vitamin D3 6,00,000 Units | 9.56 | 9.52 | 9.44 | 9.40 |
| Oral Vitamin D3 | 9.24 | 9.28 | 9.40 | 9.28 |
5 other studies available for 1-anilino-8-naphthalenesulfonate and Osteoporosis
| Article | Year |
|---|---|
Marked elevation of transaminases and pancreatic enzymes in severe malnourished male with eating disorder.
Topics: Alanine Transaminase; Anorexia; Aspartate Aminotransferases; Combined Modality Therapy; Creatine Kin | 2013 |
The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy.
Topics: Acid Phosphatase; Amidohydrolases; Bone and Bones; Calcium; Cannabinoid Receptor Modulators; Cell Co | 2011 |
Synthesis and in vitro biocompatibility of injectable polyurethane foam scaffolds.
Topics: Animals; Bacterial Proteins; Bone Substitutes; Cell Line; Fractures, Compression; Humans; Lipase; Ma | 2006 |
Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis.
Topics: Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Cholesterol; Cholesterol, HDL; Chole | 1982 |
Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Bone Density; Case-Control Studies; Cysti | 2001 |
Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Bone Density; Case-Control Studies; Cysti | 2001 |
Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Bone Density; Case-Control Studies; Cysti | 2001 |
Diminished and erratic absorption of ergocalciferol in adult cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Bone Density; Case-Control Studies; Cysti | 2001 |